Medical News Today: What to know about psoriasis and tinea versicolor

Psoriasis and tinea versicolor are two skin conditions that can cause red, scaly bumps on the skin. In this article, we look at the differences between the two conditions, including their treatment.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Psoriasis Source Type: news

Related Links:

CONCLUSION: The ULISSE study indicated that enthesitis is a common feature in patients with PsA, those with psoriasis, and in those with FMS if only clinical examination is used. US entheseal assessment showed findings more consistent with the 3 disorders. PMID: 30877205 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
AbstractIL-17 blockers are among the newer anti-psoriatic treatment options and little is known about the interclass switching. We have thus initiated a multi-center, multi-national, retrospective study to assess the treatment response of patients who were switched from one IL-17 blocker to another. Analysis consisted of data from patients with moderate-to-severe psoriasis who did not respond satisfactorily to one of the available IL-17 blockers (secukinumab, ixekizumab, brodalumab) and were subsequently  switched to another drug of this class. After 12 weeks of treatment, patients’ PASIs were evaluated. Treatme...
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
ConclusionCertolizumab is efficacious in both psoriasis and PsA, including in patients who are biologic failures, and could be considered as an alternative treatment modality.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
Herpes zoster (HZ) incidence is linked to immunosuppression. Patients with psoriasis (PsO) and/or psoriatic arthritis (PsA) on systemic therapy may be at increased risk for HZ.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Condition:   Psoriasis Vulgaris Intervention:   Drug: oral vitamin D Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Psoriasis Interventions:   Drug: Risankizumab;   Device: Autoinjector Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Psoriasis Interventions:   Drug: Risankizumab;   Drug: Placebo Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Psoriasis Vulgaris Intervention:   Drug: oral vitamin D Sponsor:   Assiut University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Psoriasis Interventions:   Drug: Risankizumab;   Device: Autoinjector Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Psoriasis Interventions:   Drug: Risankizumab;   Drug: Placebo Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Health | Psoriasis | Skin